CYSLTR1 and urinary bladder carcinoma: Interestingly, CysLT1R antagonist treatment has been shown to inhibit growth of a series of human urological cancer cell lines (e.g., renal cell carcinoma, bladder cancer, prostate cancer, and testicular cancer) by inducing apoptosis [46].